Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Shaman Pharmaceuticals has been moving on big, relative, -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Shaffer who wrote (811)	12/6/2000 1:11:04 AM
From: JMarcus	Read Replies (2) \| Respond to of 838

Glad to hear that Steve King hasn't thrown in the towel. The company has great products -- just lousy management. The company has run out of money. Last 10Q said they'd be broke by end of November. I'm worried (and the market seems to be worried) that management will do another desperate dilution financing to stay afloat while they wait for revenues to arrive from GNC. The entire problem is that GNC has been late with the launch of NSF, but Shaman management kept spending money like the on-time launch of NSF by GNC was a sure thing. Remember, Lisa assured us that the company would be at a cash flow break-even status by the end of the year. If the company can just run on fumes until GNC launches NSF either this month or next (last I talked to management, they reported that GNC was predicting a December or January product launch), we might be able to turn the corner and emerge in good shape. I'm keeping my fingers crossed, but I'm done throwing money at this investment until it gathers solid momentum on the upside. Marc